FLASH Research Garners World-Wide Interest and Reinforces TibaRay’s Strategy

The second annual FLASH Radiotherapy and Particle Therapy (FRPT) Conference was held in Barcelona, Spain in December 2022. More than 600 global participants attended the conference, whose objective was to promote the rigorous scientific study of FLASH therapy. Diverse presentation topics included studies exploring the fundamental biological mechanisms of FLASH therapy, technological developments, veterinary studies, and clinical trials. A common theme throughout the conference was the replication of the “FLASH effect" across multiple experimental models from independent researchers.

“Leading investigators around the world presented ample data at the FRPT Conference continuing to validate the FLASH biological phenomenon, deepening the tremendous excitement in the field and anticipation for bringing FLASH to the clinic for patients with cancer. There was also broad expert consensus that for patients, it will be crucial to combine FLASH with exquisitely sculpted 3D distribution of radiation dose, a major technological challenge," said Prof. Bill Loo, MD PhD, founder of TibaRay and Director of Thoracic Radiation Oncology and Director of New Technologies in Radiation Oncology at Stanford Cancer Institute. This provides further confirmation that TibaRay is on the cusp of redefining the future of cancer treatment with our innovative PHASER system. TibaRay technology is uniquely positioned to deliver the benefits of highly conformal FLASH therapy, eXactFLASH^TM, as we make treatment more accessible to patients with all types and stages of cancer, all over the world.

For more information on the second annual FRPT conference, visit https://frpt-conference.org.

Delegates attending FRPT 2022: